Adverum Biotechnologies, Inc. (ADVM)
Dec 9, 2025 - ADVM was delisted (reason: acquired by LLY)
4.360
+0.100 (2.35%)
Inactive · Last trade price
on Dec 8, 2025
Adverum Biotechnologies Revenue
In the year 2024, Adverum Biotechnologies had annual revenue of $1.00M, down -72.22%.
Revenue (ttm)
$1.00M
Revenue Growth
-72.22%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
155
Market Cap
96.26M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionADVM News
- 3 months ago - Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - PRNewsWire
- 3 months ago - Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM - Business Wire
- 4 months ago - Eli Lilly to buy gene therapy developer Adverum in about $262 million deal - Reuters
- 4 months ago - Lilly to Acquire Adverum Biotechnologies - PRNewsWire
- 6 months ago - Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration - GlobeNewsWire
- 6 months ago - Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewsWire